Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Pharmacogenomics in autism treatment  

Risperidone, the most studied atypical antipsychotic used in children, has been shown to improve severe behavioral symptoms in over half of children with autism with these problems. However, not all children with autism and severe behavioral problems respond to risperidone, and for a few, it has significant side effects. Blood genomic profiles are shown to predict medication response for disorders such as cancer and epilepsy. This study will use blood genomic profiles before and after risperidone treatment in children with autism and severe behavioral problems to determine if the profiles can predict response to treatment. The ultimate goal of this line of research is to develop methods to predict which medications work for which child before initiating treatment, to predict which child might develop particular side effects, and to identify new treatment targets for future medication development. Project Status
NEW

2009

Funder National Institutes of Health
Fiscal Year Funding $121,239.00
Project Number 7R21MH080026-03
Principal Investigator Hendren, Robert
Received ARRA Funding? No
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Interventions)
Strategic Plan Objective Yellow dot: Objective has some degree of funding, but less than the recommended amount. 4LC. Conduct at least one study to evaluate the safety and effectiveness of medications commonly used in the treatment of co-occurring conditions or specific behavioral issues in people with ASD by 2015. IACC Recommended Budget: $10,000,000 over 5 years.
Federal or Private? Federal
Institution University of California, Davis
State/Country California
Web Link 1 Pharmacogenomics in autism treatment (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
New! History/Related Projects Pharmacogenomics in autism treatment | $83,961.00 | 2009 | 5R21MH080026-02
Pharmacogenomics in autism treatment | $171,000.00 | 2008 | R21MH080026-01A1